研究单位：[1]Chengdu Kanghong Biotech Co., Ltd.[2]Beijing Tongren hospital affiliated to Capital Medical University,Beijing,China,100730[3]The Affiliated Eye Hospital of WMC,Wenzhou,Zhejiang,China,325027
研究目的：
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment period (3 months) and a PRN period (6 months). In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.
